Healthcare Industry News: IMRT
News Release - October 29, 2010
RaySearch Laboratories: Massachusetts General Hospital in Boston Chooses RaySearch’s Treatment Planning System RayStation(R)STOCKHOLM--(Healthcare Sales & Marketing Network)--Massachusetts General Hospital (MGH) in Boston, USA, has selected RaySearch’s treatment planning system RayStation® as their next generation planning software for delivery of IMRT and VMAT treatments.
In 2008, RaySearch (STO:RAYB.st ) and MGH entered into a long-term research and development collaboration within the field of multi-criteria optimization for radiation therapy. In all radiation treatments, the clinician has to balance conflicting objectives such as obtaining a sufficiently high target dose to achieve tumor control, while ensuring that the dose to the surrounding healthy tissues is sufficiently low to minimize the risk for side effects. Multi-criteria optimization provides a tool for dealing with these tradeoffs in a stringent fashion. This has the potential to speed up the time-consuming treatment planning optimization process where currently the parameters of a treatment plan are changed through trial and error until a satisfactory plan is found.
The cooperation has resulted in a software product that enables clinicians to explore and evaluate a representative set of treatment alternatives in a highly intuitive and efficient way. The solution is now integrated in RaySearch’s proprietary RayStation® treatment planning system. The new agreement means that MGH licenses RayStation® for treatment planning of advanced IMRT and VMAT treatments and brings the solution for multi-criteria optimization into clinical practice for the first time.
RayStation® integrates all RaySearch’s advanced treatment planning solutions into one flexible system. In addition to the unique multi-criteria optimization tools, it also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization, highly accurate dose engines for both photon and proton therapy and has full support for 4D adaptive radiation therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.
“MGH is one of the most renowned clinics in the United States and we are of course honored that they have selected RayStation® as their new treatment planning system. Our research collaboration has been very successful and I look forward to continuing our partnership in a clinical setting,” says Johan Löf, CEO of RaySearch.
“The order will generate revenues for the fourth calendar quarter but has no impact on the financial results for the third quarter that will be presented on November 12th. The third quarter is generally the weakest during the year due to seasonal effects and 2010 is no exception. However, delivering RayStation® to such an advanced and prestigious clinic as MGH, is a very important strategic milestone that will have long-term positive effects for RaySearch,” concludes Johan Löf.
RaySearch will participate as an exhibitor at the annual ASTRO radiation therapy meeting, which this year will be held in San Diego, October 31 to November 4, and will demonstrate RayStation® in booth 2228.
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Varian, Siemens, Nucletron, IBA Dosimetry and TomoTherapy. To date, 15 products have been launched through partners and RaySearch’s software is used at some 1,500 clinics in more than 30 countries. In addition, existing license agreements cover more than 15 other products that are scheduled to be launched in the coming years. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.
For more information about RaySearch, visit www.raysearchlabs.com.
Source: RaySearch Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.